The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: John Crary
Project Title: Neuropathological studies of primary age-related tauopathy: the PART working group
Date: December 21, 2021 at 5:02 pm
Request ID: T1512
Aim 1: Aim 1. To validate the neuropathological criteria for PART and lay the groundwork for clinical and mechanistic studies that will elucidate disease burden, pathogenesis and progression.
Aim 2: Aim 2. To test the hypothesis that PART has a molecular signature consisting of AD-type tau pathology alongside non-amyloidogenic APP metabolites.
Aim 3: Aim 3. To test the hypothesis that PART has a genetic risk profile that overlaps with some aspects of AD genetics (e.g., MAPT haplotypes) but diverges with respect to others (e.g., APOE genotype).
Aim 4:
Investigator: Eric A. Schon
Project Title: Diagnosis of AD based on perturbed MAM function in blood and CSF
Date: December 21, 2021 at 5:02 pm
Request ID: T1716
Aim 1: To test the hypothesis that AD can be diagnosed in blood (e.g. whole blood, fractionated blood components, plasma, and serum) and/or CSF based on the analysis of phenotypes associated with increased ER-mitochondrial communication
Aim 2:
Aim 3:
Aim 4:
Investigator: Carlos Cruchaga and Jin-Moo Lerr
Project Title: Contribution of vascular disease to Alzheimer dementia
Date: December 21, 2021 at 5:02 pm
Request ID: T1610
Aim 1: Aim 1: Develop precise imaging biomarker of vascular burden by identifying distinct white matter hyperintensity patterns that are highly correlated with cerebrovascular disease and/or vascular risk factors in a mixed cohort of AD, healthy aging and stroke patients.
Aim 2: Aim2: Validate the novel biomarker for stroke and vascular dementia.
Aim 3:
Aim 4:
Investigator: G. William Rebeck
Project Title: APOE ISOFORM-SPECIFIC GLYCOSYLATION IN ALZHEIMER�S DISEASE
Date: December 21, 2021 at 5:02 pm
Request ID: T1611
Aim 1: identify glycosylated forms of APOE in human plasma
Aim 2: determine whether plasma glyco-APOE species differ by APOE genotype
Aim 3: determine whether plasma glyco-APOE species are altered in Alzheimer’s disease
Aim 4:
Investigator: Allen D. Roses, MD
Project Title: TOMM40-‘523 haplotype relationship to age of onset of dementia
Date: December 21, 2021 at 5:02 pm
Request ID: T1612
Aim 1: Compare the TOMM40-‘523 genotype calls previously obtained with Sanger Sequencing Assay Results
Aim 2: Analyze the interaction between APOE and TOMM40 genotypes and ae of onset of symptomatic Alzheimer’s Disease
Aim 3:
Aim 4:
Investigator: J. Randall Slemmon Ph.D.
Project Title: Tau Fragment CSF Biosignature in AD
Date: December 21, 2021 at 5:02 pm
Request ID: T1613
Aim 1: Determine if the pTau fragment profile changes in CSF during the course of AD.
Aim 2: Determine if the totalTau fragment profile (mid-mid region) changes in CSF during the course of AD.
Aim 3:
Aim 4:
Investigator: A Fagan
Project Title: Prospective Measures of Outcome in Rapidly Progressive Dementia
Date: December 21, 2021 at 5:02 pm
Request ID: T1614
Aim 1: Determine clinically-measurable variables that differentiate between patients with various forms of RPD
Aim 2: Quantify neuroinflammation, neurodegeneration, and synaptic dysfunction in patients with RPD utilizing cerebrospinal fluid measures
Aim 3: Evaluate associations between biomarkers (Aim 2) and clinical outcomes (including cognitive performance) measured in individuals with RPD
Aim 4:
Investigator: David Holtzman
Project Title: Validation of novel human apoE antibody staining in human AD tissue
Date: December 21, 2021 at 5:02 pm
Request ID: T1719
Aim 1: Determine whether novel human apoE antibody detects apoE in plaques from AD patients
Aim 2:
Aim 3:
Aim 4:
Investigator: Jerold Chun
Project Title: Neural Genomic Mosaicism (NGM) in Neurodegenerative disorders
Date: December 21, 2021 at 5:02 pm
Request ID: T1718
Aim 1: Identify NGM changes defined by DNA content variation (DCV) that track with neurodegenerative diseases
Aim 2: Conduct small population and single-cell genomic and transcriptomic analyses on positive samples from Aim 1 to identify altered genes and pathways
Aim 3:
Aim 4:
Investigator: Beth Stevens
Project Title: of Microglia and Complement in Synapse Loss in Alzheimer�s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1715
Aim 1: Examine synapse-associated complement proteins in human AD tissue
Aim 2: Examine synaptic proteins inside microglia in human AD tissue
Aim 3:
Aim 4: